Completed PHASE2 INTERVENTIONAL 2-arm NCT02596308

Immunogenicity and Safety of Subunit Plague Vaccine

Immunogenicity and Safety of Subunit Plague Vaccine Comprised by Fraction 1 Capsule (F1) and Virulence-Associated (V) Antigens: A Random Phase 2a Clinical Trial

Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Conditions Plague

Interventions Plague vaccine

Updated 4 times since 2017 Last updated: Nov 2, 2015 Started: Oct 31, 2014 Primary completion: Dec 31, 2014 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Plague and is currently completed. Jiangsu Province Centers for Disease Control and Prevention leads this study, which shows 4 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Province Centers for Disease Control and Prevention
Lanzhou Institute of Biological Products Co., Ltd

Data source: Jiangsu Province Centers for Disease Control and Prevention

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China